Retham Technologies, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersMilwaukee, WI
SAM.gov UEIKDM9HGS7NFT9
Retham Technologies develops an in vitro diagnostic (IVD) assay called HITDx for the diagnosis of Heparin-induced Thrombocytopenia (HIT). The company references PF4 ELISAs and the Serotonin release assay as existing diagnostic tests for HIT, a serious adverse reaction to the blood thinner heparin that can cause blood clotting and life-threatening complications.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Retham Technologies, INC. | Milwaukee | WI | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.